U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192237) titled 'Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia' on Sept. 23.
Brief Summary: To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Study Start Date: Feb. 27, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 2 Study
Blinatumomab
Acute Lymphoblastic Leukemia
Intervention:
DRUG: Blinatumomab
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Con...